The goal of this clinical research study is to find the highest tolerable dose of TTP607 that
can be given to patients with a solid tumor or lymphoma. The safety of TTP607 will also be
studied.
Researchers will also do pharmacokinetic (PK) testing of TTP607. PK testing measures the
amount of a drug in the body at different time points.